Dare Bioscience reports Q1 EPS (50c), consensus (58c)

“The first quarter of 2025 has been marked by distractions and disruptions for the overall healthcare and biotech sector. I am proud that Dare is uniquely positioned to cut through the noise and deliver value to all of our stakeholders – women, healthcare providers, and investors. Today, biopharmaceutical companies with relatively low risk assets, a competitive advantage and a path toward near-term revenue are positioned to offer upside. We believe that is Dare today,” said Sabrina Martucci Johnson, president and CEO of Dare Bioscience (DARE). “Women’s health is ripe for returns because it has been underfunded and fragmented – and with our recently announced expanded business strategy, we believe we are uniquely positioned to deliver value and returns to all of our stakeholders, with a business model that is nimble, allowing us to rapidly commercialize multiple products via multiple channels. We are no longer only seeking FDA approval; we are leveraging a dual path strategy where we commercialize via 503B compounding while continuing to seek FDA approval. We are also taking steps toward launching certain solutions as branded consumer health products that do not require a prescription.”